Have a feature idea you'd love to see implemented?
Let us know!
VTGN VistaGen Therapeutics Inc
Price (delayed)
$3.03
Market cap
$81.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.48
Enterprise value
-$18.95M
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and
Highlights
VistaGen Therapeutics's EPS has soared by 78% YoY and by 2.6% from the previous quarter
The company's debt fell by 39% YoY and by 6% QoQ
The net income has increased by 28% year-on-year but it has declined by 13% since the previous quarter
VTGN's quick ratio is down by 25% since the previous quarter
VistaGen Therapeutics's revenue has decreased by 9% QoQ
Key stats
What are the main financial stats of VTGN
Market
Valuations
Earnings
Shares outstanding
27.06M
Market cap
$81.98M
Enterprise value
-$18.95M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.78
Price to sales (P/S)
95.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-19.53
Revenue
$970,400
EBIT
-$33.19M
EBITDA
-$32.61M
Free cash flow
-$28.89M
Per share
Balance sheet
Liquidity
EPS
-$1.48
Free cash flow per share
-$0.94
Book value per share
$3.88
Revenue per share
$0.03
TBVPS
$3.71
Total assets
$113.55M
Total liabilities
$8.75M
Debt
$1.99M
Equity
$104.8M
Working capital
$104.6M
Debt to equity
0.02
Current ratio
17.77
Quick ratio
17.38
Net debt/EBITDA
3.1
Margins
Efficiency
Dividend
EBITDA margin
-3,360.4%
Gross margin
100%
Net margin
-3,420.4%
Operating margin
-3,931.8%
Return on assets
-32.3%
Return on equity
-35.1%
Return on invested capital
-914.1%
Return on capital employed
-30.9%
Return on sales
-3,420.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTGN stock price
How has the VistaGen Therapeutics stock price performed over time
Intraday
0%
1 week
-0.98%
1 month
0.66%
1 year
1.68%
YTD
-41.05%
QTD
0.66%
Financial performance
How have VistaGen Therapeutics's revenue and profit performed over time
Revenue
$970,400
Gross profit
$970,400
Operating income
-$38.15M
Net income
-$33.19M
Gross margin
100%
Net margin
-3,420.4%
The net income has increased by 28% year-on-year but it has declined by 13% since the previous quarter
The operating margin is down by 27% since the previous quarter
The company's net margin fell by 24% QoQ
The company's operating income rose by 18% YoY but it fell by 16% QoQ
Growth
What is VistaGen Therapeutics's growth rate over time
Valuation
What is VistaGen Therapeutics stock price valuation
P/E
N/A
P/B
0.78
P/S
95.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-19.53
VistaGen Therapeutics's EPS has soared by 78% YoY and by 2.6% from the previous quarter
The price to book (P/B) is 77% lower than the 5-year quarterly average of 3.4 and 35% lower than the last 4 quarters average of 1.2
The equity has decreased by 8% QoQ
VistaGen Therapeutics's revenue has decreased by 9% QoQ
The price to sales (P/S) is 8% lower than the last 4 quarters average of 103.9
Efficiency
How efficient is VistaGen Therapeutics business performance
The ROE has soared by 87% YoY and by 16% from the previous quarter
The company's return on assets has surged by 81% YoY and by 14% QoQ
The company's return on invested capital rose by 32% YoY
VistaGen Therapeutics's ROS has decreased by 24% from the previous quarter
Dividends
What is VTGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTGN.
Financial health
How did VistaGen Therapeutics financials performed over time
VTGN's quick ratio is down by 25% since the previous quarter
The current ratio has decreased by 25% from the previous quarter
The company's debt is 98% lower than its equity
VTGN's debt to equity has dropped by 96% year-on-year
The company's debt fell by 39% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.